Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
New York Genome Center | RCV002266606 | SCV002548629 | uncertain significance | Nizon-Isidor syndrome | 2021-06-17 | criteria provided, single submitter | clinical testing | |
Prevention |
RCV003418431 | SCV004106796 | uncertain significance | MED12L-related disorder | 2023-03-27 | criteria provided, single submitter | clinical testing | The MED12L c.701A>G variant is predicted to result in the amino acid substitution p.Glu234Gly. To our knowledge, this variant has not been reported in the literature. This variant is reported in 0.0030% of alleles in individuals of Latino descent in gnomAD (http://gnomad.broadinstitute.org/variant/3-150874092-A-G). At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. |
Ambry Genetics | RCV004958522 | SCV005444365 | uncertain significance | Inborn genetic diseases | 2024-11-24 | criteria provided, single submitter | clinical testing | The c.701A>G (p.E234G) alteration is located in exon 5 (coding exon 5) of the MED12L gene. This alteration results from a A to G substitution at nucleotide position 701, causing the glutamic acid (E) at amino acid position 234 to be replaced by a glycine (G). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |